MEDI-538

DRUG2 trials

Sponsors

MedImmune LLC

Conditions

Chronic Lymphocytic LeukemiaLymphoma, B-CellLymphoma, Non-Hodgkin

Phase 1

A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma

WithdrawnNCT00538096

MedImmune LLCLymphoma, B-Cell, Lymphoma, Non-Hodgkin

Start: 2007-09-30End: 2010-05-31Target: 18Updated: 2008-09-05

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)

WithdrawnNCT00676871

MedImmune LLCChronic Lymphocytic Leukemia

Start: 2008-06-30End: 2011-06-30Target: 30Updated: 2008-09-05